Chugai Pharmabody Research
Singapore, Singapore· Est.
CPR pioneers antibody and cyclic peptide drug discovery to address unmet medical needs worldwide.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
CPR pioneers antibody and cyclic peptide drug discovery to address unmet medical needs worldwide.
OncologyImmunologyHematologyInfectious Disease
Technology Platform
Proprietary antibody engineering combined with cyclic peptide design enables generation of high‑affinity biologics and conformationally constrained peptides for traditionally undruggable targets.
Opportunities
Leveraging Roche’s global development pipeline and expanding collaborations with academic institutions can accelerate CPR’s transition from pre‑clinical to clinical stages across multiple therapeutic areas.
Risk Factors
Heavy reliance on parent company funding and the inherent scientific uncertainty of novel cyclic peptide modalities could delay product timelines.
Competitive Landscape
CPR differentiates itself through its combined antibody‑cyclic peptide platform, competing with traditional biologics firms such as Amgen and Regeneron, while offering unique access to intracellular targets.